Positron emission tomography of 18F-big endothelin-1 reveals renal excretion but tissue-specific conversion to 18F-endothelin-1 in lung and liver

British Journal of Pharmacology

Volumn 159, Issue 4, 2010, Pages 812-819

  Johnström, Peter ^a   Fryer, Tim D ^b   Richards, Hugh K ^a   Maguire, Janet J ^a   Clark, John C ^b   Pickard, John D ^a,b   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

18F ET; Big ET 1; Endothelin converting enzyme; ET 1; FR139317; In vivo imaging; MicroPET; Phosphoramidon; Positron emission tomography

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; BIG ENDOTHELIN 1; BIG ENDOTHELIN 1 F 18; ENDOTHELIN 1; ENDOTHELIN 1 F 18; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PHOSPHORAMIDON; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE IMAGING; HEART; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY PAPILLA; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; RECEPTOR BINDING; SPLEEN; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; AUTORADIOGRAPHY; AZEPINES; ENDOTHELIN-1; ENZYME ACTIVATION; FLUORINE RADIOISOTOPES; GLYCOPEPTIDES; HALF-LIFE; INDOLES; INFUSIONS, INTRAVENOUS; KIDNEY; LUNG; MALE; METALLOENDOPEPTIDASES; MOLECULAR IMAGING; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 77249163226     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00641.x     Document Type: Article

References (43)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Bacon CR, Cary NRB, Davenport AP (1996). Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 79 : 794 801.
3. Brooks C, Ergul A (1998). Identification of amino acid residues in the C-terminal tail of big endothelin-1 involved in processing to endothelin-1. J Mol Endocrinol 21 : 307 315.
4. Chatziioannou AF (2002). Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 29 : 98 114.
5. Davenport AP, Kuc RE (2005). Immunocytochemical localization of receptors using light and confocal microscopy with application to the phenotypic characterization of knock-out mice. Methods Mol Biol 306 : 155 172.
6. Davenport AP, Kuc RE, Mockridge JW (1998). Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells. J Cardiovasc Pharmacol 31 (Suppl. 1 S1 S3.
7. Davenport AP, Maguire JJ (2006). Endothelin. Handb Exp Pharmacol 176 : 295 329.
8. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I et al. (1998). Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135 : 614 620.
9. Dupuis J, Stewart DJ, Cernacek P, Gosselin G (1996). Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94 : 1578 1584.
10. Gardiner SM, Compton AM, Kemp PA, Bennett T (1991). The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin 1-38 in conscious rats. Br J Pharmacol 103 : 2009 2015.
11. Gardiner SM, Kemp PA, Bennett T (1993). Regional haemodynamic responses to intravenous and intraarterial endothelin-1 and big endothelin-1 in conscious rats. Br J Pharmacol 110 : 1532 1536. (Pubitemid 23360990)
12. Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T (1997). Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats. Br J Pharmacol 122 : 1687 1693.
13. Grantham JA, Grantham JA, Schirger JA, Williamson EE, Heublein DM, Wennberg PW et al. (1998). Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol 31 (Suppl. 1 S22 S26.
14. Haynes WG, Webb DJ (1998). Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16 : 1081 1098.
15. Jeng AY (2003). Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Curr Opin Investig Drugs 4 : 1076 1081.
16. Jeng AY, Mulder P, Kwan AL, Battistini B (2002). Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 80 : 440 449.
17. Johnström P, Fryer TD, Richards HK, Barret O, Davenport AP (2005b). Dynamic in vivo imaging of receptors in small animals using positron emission tomography. Methods Mol Biol 306 : 217 232.
18. B receptors in vivo. Br J Pharmacol 144 : 115 122.
19. Johnström P, Harris NG, Fryer TD, Barret O, Clark JC, Pickard JD et al. (2002). 18F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET. Clin Sci (Lond) 103 (Suppl. 48 4S 8S.
20. Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M et al. (1989). Conversion of big endothelin-1-21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 13 (Suppl. 5 S5 S7.
21. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y et al. (1988). Structure-activity relationships of endothelin: importance of the C-terminal moiety. Biochem Biophys Res Commun 156 : 1182 1186.
22. Kinahan PE, Rogers JG (1989). Analytic 3D image-reconstruction using all detected events. IEEE Trans Nucl Sci 36 : 964 968.
23. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ (2002). Small animal imaging. current technology and perspectives for oncological imaging. Eur J Cancer 38 : 2173 2188.
24. McMahon EG, Palomo MA, Moore WM, McDonald JF, Stern MK (1991). Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 88 : 703 707.
25. Maguire JJ, Davenport AP (1998). Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol 125 : 238 240.
26. Maguire JJ, Johnson CM, Mockridge JW, Davenport AP (1997). Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol 122 : 1647 1654.
27. Martinet JP, Legault L, Cernacek P, Roy L, Dufresne MP, Spahr L et al. (1996). Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites. J Hepatol 25 : 700 706.
28. Matsumoto H, Suzuki N, Kitada C, Fujino M (1994). Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides 15 : 505 510.
29. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H et al. (1997). Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 95 : 221 230.
30. Mombouli JV, Le SQ, Wasserstrum N, Vanhoutte PM (1993). Endothelins 1 and 3 and big endothelin-1 contract isolated human placental veins. J Cardiovasc Pharmacol 22 (Suppl. 8 S278 S281.
31. Naruse K, Naruse M, Watanabe Y, Yoshihara I, Ohsumi K, Horiuchi J et al. (1991). Molecular form of immunoreactive endothelin in plasma and urine of normal subjects and patients with various disease states. J Cardiovasc Pharmacol 17 (Suppl. 7 S506 S508.
32. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD et al. (1988). Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 185 : 9797 9800.
33. Okada K, Arai Y, Hata M, Matsuyama K, Yano M (1993). Big endothelin-1 structure important for specific processing by endothelin-converting enzyme of bovine endothelial cells. Eur J Biochem 218 : 493 498.
34. Okada K, Takada J, Arai Y, Matsuyama K, Yano M (1991). Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme. Biochem Biophys Res Commun 180 : 1019 1023.
35. Plumpton C, Haynes WG, Webb DJ, Davenport AP (1995). Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol 116 : 1821 1828.
36. Plumpton C, Kalinka S, Martin RC, Horton JK, Davenport AP (1994). Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays. Clin Sci (Lond) 87 : 245 251.
37. Pollock DM, Opgenorth TJ (1991a). Comparison of the hemodynamic effects of endothelin-1 and big endothelin-1 in the rat. Biochem Biophys Res Commun 179 : 1122 1126.
38. Pollock DM, Opgenorth TJ (1991b). Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1. Am J Physiol 261 : R257 R263.
39. Robb RA, Hanson DP, Karwoski RA, Larson AG, Workman EL, Stacy MC (1989). Analyze: a comprehensive, operator-interactive software package for multidimensional medical image display and analysis. Comput Med Imaging Graph 13 : 433 454.
40. Russell FD, Davenport AP (1999). Secretory pathways in endothelin synthesis. Br J Pharmacol 126 : 391 398.
41. Suzuki N, Matsumoto H, Kitada C, Kimura S, Miyauchi T, Fujino M (1990). A sandwich-type enzyme immunoassay to detect immunoreactive big-endothelin-1 in plasma. J Immunol Methods 127 : 165 170.
42. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL et al. (2001). Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol 46 : 1845 1862.
43. Watanabe Y, Naruse M, Monzen C, Naruse K, Ohsumi K, Horiuchi J et al. (1991). Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 17 (Suppl. 7 S503 S505.